急性缺血性卒中不同剂量阿替普酶静脉溶栓疗效比较

中国卒中杂志 ›› 2014, Vol. 9 ›› Issue (07): 551-556.

急性缺血性卒中不同剂量阿替普酶静脉溶栓疗效比较

廖晓凌，王伊龙，潘岳松，王春娟，赵性泉，王春雪，刘丽萍，王拥军

100050 北京
首都医科大学附属北京
天坛医院神经内科

收稿日期:2013-08-13 出版日期:2014-07-20 发布日期:2014-07-20
通讯作者: 王拥军 y o n g j u nwa n g 1 9 6 2@ gmail.com
基金资助:
“十二五”国家科技支撑
计划（2011BAI08B02）
“十一五”国家科技支撑
计划（2006BAI01A11）
北京市科委2011年度科
技计划重大项目——
《缺血性脑卒中高危预警
体系建立和规范研究》
（No.D111107003111007）

Comparison of the Efficacy and Safety of Acute Ischemic Stroke Patients Receiving Different Dose Intravenous Alteplase

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing
100050, China

Received:2013-08-13 Online:2014-07-20 Published:2014-07-20

摘要/Abstract

摘要：

目的对不同剂量阿替普酶静脉溶栓治疗人群进行比较，探讨对于中国急性缺血性卒中人群，标准剂量与低剂量阿替普酶是否具有一样的安全性及有效性。方法本研究的入选患者来自中国急性缺血性卒中溶栓监测登记研究，从中选取发病4.5 h内且阿替普酶使用剂量约为0.6 mg/kg（0.5～0.7 mg/kg）及0.9 mg/kg（0.85～0.95 mg/kg）的静脉溶栓患者，对溶栓后症状性颅内出血（symptomatic intracranial hemorrhage，SICH）、死亡率及90 d随访结局等进行比较。结果共入选753例患者，0.5～0.7 mg/kg组75例，0.85～0.95 mg/kg组678例，两组剂量中位数分别为0.64 mg/kg及0.90 mg/kg，发病-给药时间中位数分别为2.92 h及2.79 h。在校正了基线变量差异后，两组的死亡率（5.41% vs 7.36%，P =0.603）及SICH（0% vs 1.62%，P =0.972）均无显著差异，而 0.5～0.7 mg/kg 组90 d随访获得良好预后的比例显著低于0.85～0.95 mg/kg组［41.89% vs 53.83%，比值比（odds ratio，OR）=0.58，P =0.031）］。结论本研究提示，在中国人群中，标准剂量（0.9 mg/kg）较低剂量（0.6 mg/kg）阿替普酶静脉溶栓具有更好的有效性，且不会显著增加SICH风险。

文章导读： 通过对不同剂量阿替普酶静脉溶栓治疗中国人群急性缺血性卒中的对比，显示0.9 mg/kg标准剂
量治疗预后优于0.6 mg/kg剂量。

关键词: 急性缺血性卒中" 溶栓" 有效性" 安全性

Abstract:

Objective To investigate whether lower-dose intravenous alteplase is as effective and safe as the standard-dose for Chinese population of acute ischemic stroke by comparing different doses of alteplase used in China. Methods We analyzed data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China). Patients who were treated within 4.5 h after symptom onset and with dose of about 0.6 mg/kg (0.5~0.7 mg/kg) or 0.9 mg/kg (0.85~0.95 mg/kg) were included. Symptomatic intracranial hemorrhage (SICH), mortality and 90-day outcome of these patients were analyzed. Results A total of 753 patients were enrolled into the study. Among them, 75 had 0.5~0.7 mg/kg and 678 had 0.85~0.95 mg/kg. Median alteplase doses were 0.64 mg and 0.90 mg, respectively. Median stroke onset to treatment time were 2.92 h and 2.79 h (P =0.252). After adjustment for the baseline variables, there were no significant differences in mortality (5.41% vs 7.36%, P =0.603) and SICH (0% vs 1.62%, P =0.972). The 0.5~0.7 mg/kg group had less good functional outcome than that in the 0.85~0.95 mg/kg group (41.89% vs 53.83%, [odds ratio, OR]=0.58, P =0.031) at 90 day. Conclusion Our study suggests that stroke patients receiving standard-dose (0.9 mg/kg) alteplase had more favorable outcome without increasing the risk of SICH than those receiving low-dose (0.6 mg/kg) alteplase. For Chinese people, 0.9 mg/kg should be the optimal dose of alteplase to treat acute ischemic stroke.

Key words: Acute ischemic stroke; Thrombolytic treatment; Efficacy; Safety

廖晓凌，王伊龙，潘岳松，王春娟，赵性泉，王春雪，刘丽萍，王拥军. 急性缺血性卒中不同剂量阿替普酶静脉溶栓疗效比较[J]. 中国卒中杂志, 2014, 9(07): 551-556.

LIAO Xiao-Ling, WANG Yi-Long, PAN Yue-Song,WANG Chun-Juan, ZHAO Xing-Quan, WANG Chun-Xue, LIU Li-Ping, WANG Yong-Jun.. Comparison of the Efficacy and Safety of Acute Ischemic Stroke Patients Receiving Different Dose Intravenous Alteplase[J]. Chinese Journal of Stroke, 2014, 9(07): 551-556.

参考文献

1 The National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke[J]. N Engl J Med,

1995, 333:1581-1587.

2 Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis

with alteplase 3 to 4.5 hours after acute ischemic

stroke[J]. N Engl J Med, 2008, 359:1317-1329.

3 Dharmasaroja PA, Pat taraarchachai J. Low vs

standard dose of recombinant tissue plasminogen

activator in treating East Asian patients with acute

ischemic stroke[J]. Neurol India, 2011, 59:180-184.

4 Chen CH, Hsieh CY, Lai TB, et al. Optimal dose for stroke thrombolysis in Asians:low dose may have

similar safety and efficacy as standard dose[J]. J

Thromb Haemost, 2012, 10:1270-1275.

5 Sharma VK, Ng KW, Venketasubramanian N, et al.

Current status of intravenous thrombolysis for acute

ischemic stroke in Asia[J]. Int J Stroke, 2011, 6:523-530.

6 Nakagawa ra J, Minematsu K, Okada Y, et al.

Thrombolysis with 0.6 mg/kg intravenous alteplase for

acute ischemic stroke in routine clinical practice:the

Japan post-Marketing Alteplase Registration Study

(J-MARS)[J]. Stroke, 2010, 41:1984-1989.

7 Yamaguchi T, Mori E, Minematsu K, et al. Alteplase

at 0.6 mg/kg for acute ischemic stroke within 3 hours

of onset:Japan Alteplase Clinical Trial (J-ACT)[J].

Stroke, 2006, 37:1810-1815.

8 Liao XL, Wang CX, Wang YL, et al. Implementation

and outcome of thrombolysis with alteplase 3 to

4.5 h after acute stroke in Chinese patients[J]. CNS

Neurosci Ther, 2013, 19:43-47.

9 Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis

with alteplase for acute ischaemic stroke in the

Safe Implementation of Thrombolysis in Stroke-

Monitoring Study (SITS-MOST):an observational

study[J]. Lancet, 2007, 369:275-282.

10 Hacke W, Kaste M, Fieschi C, et al. Randomised

double-blind placebo-controlled trial of thrombolytic

therapy with intravenous alteplase in acute ischaemic

stroke (ECASS II). Second European-Australasian

Acute Stroke Study Investigators[J]. Lancet, 1998,

352:1245-1251.

11 Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy

for stroke. Part I. Pilot study of tissue plasminogen

activator administered within 90 minutes[J]. Stroke,

1992, 23:632-640.

12 Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy

for stroke. Part II. Pilot study of tissue plasminogen

activator administered 91-180 minutes from onset[J].

Stroke, 1992, 23:641-645.

13 Lees KR, Bluhmki E, von Kummer R, et al. Time

to treatment with intravenous alteplase and outcome

in stroke:an updated pooled analysis of ECASS,

ATLANTIS, NINDS, and EPITHET trials[J]. Lancet,

2010, 375:1695-1703.

14 Hacke W, Kaste M, Fieschi C, et al. Intravenous

thrombolysis with recombinant tissue plasminogen

activator for acute hemispheric stroke. The European

Cooperative Acute Stroke Study (ECASS)[J]. JAMA,

1995, 274:1017-1025.

15 Zhou XY, Wang SS, Collins ML, et al. Efficacy

and safety of different doses of intravenous tissue

plasminogen activator in Chinese patients with

ischemic stroke[J]. J Clin Neurosci, 2010, 17:988-992.

16 Chao AC, Hsu HY, Chung CP, et al. Outcomes of

thrombolytic therapy for acute ischemic stroke in

Chinese patients:the Taiwan Thrombolytic Therapy

for Acute Ischemic Stroke (TTT-AIS) study[J]. Stroke,

2010, 41:885-890.

17 Sharma VK, Tsivgoulis G, Tan JH, et al. Feasibility

and safety of intravenous thrombolysis in multiethnic

Asian stroke patients in Singapore[J]. J Stroke

Cerebrovasc Dis, 2010, 19:424-430.

18 Nguyen TH, Truong AL, Ngo MB, et al. Patients with

thrombolysed stroke in Vietnam have an excellent

outcome:results from the Vietnam Thrombolysis

Registry[J]. Eur J Neurol, 2010, 17:1188-1192.

19 Ahmad A, Sharma VK. More on:optimal dose for

stroke thrombolysis in Asians[J]. J Thromb Haemost,

2012, 10:1970-1971.

[1]	任伟超, 马宁, 张亚梅, 王铁军. 经远端桡动脉入路行数字减影血管造影的临床效果研究[J]. 中国卒中杂志, 2022, 17(11): 1216-1220.
[2]	张俊良, 黄双凤, 徐璐瑶, 向薇, 张曼曼, 梁志刚. 替罗非班治疗MRI筛选的轻中度非心源性缺血性卒中的安全性和有效性研究[J]. 中国卒中杂志, 2022, 17(01): 66-72.
[3]	钟曦, 莫大鹏. 高危非急性颈内动脉闭塞血管内治疗的研究进展[J]. 中国卒中杂志, 2021, 16(10): 979-981.
[4]	于逢春, 祁艳艳, 张敬, 高兵, 王雪红, 赵凤丽, 王素丽, 方之勇, 乔淑冬, 毕齐. 50 mg阿司匹林肠溶缓释片在轻型缺血性卒中和短暂性脑缺血发作二级预防中的安全性与有效性研究[J]. 中国卒中杂志, 2021, 16(07): 657-663.
[5]	李迪，刘舒鑫. 大脑中动脉M2段急性闭塞机械取栓临床疗效评估[J]. 中国卒中杂志, 2019, 14(07): 665-670.
[6]	李姝雅，王伊龙，郑华光，赵性泉，刘丽萍，孟霞，王拥军. 丁苯酞氯化钠注射液治疗急性缺血性卒中安全性及有效性研究——多中心、前瞻性、开放标签Ⅳ期临床试验[J]. 中国卒中杂志, 2019, 14(05): 450-455.
[7]	张荣举，王君，邸海，皮成慧，杜志华，刘新峰，曹向宇，田成林，于生元. LVIS支架在颅内动脉瘤治疗中的安全性及有效性的单中心观察性研究[J]. 中国卒中杂志, 2018, 13(08): 785-789.
[8]	吴岩峰，刘庆萍，丁红. 提高急性缺血性卒中静脉溶栓有效性和安全性的研究进展[J]. 中国卒中杂志, 2016, 11(02): 126-130.
[9]	王少石;郝俊杰;杨江胜. 他汀类药物临床应用的安全性[J]. , 2009, 4(01): 35-40.
[10]	王春雪;王拥军. 他汀类药物预防缺血性卒中/TIA的安全性[J]. , 2007, 2(04): 48-50.